Obesity remains a global public health concern and decision-makers are increasingly interested in anti-obesity medications as a treatment option. The UK Life Sciences Vision committed to accelerating the development, testing and patient availability of innovative medicines, medical technologies, digital devices, and one of the major health priorities is obesity. To realise the obesity mission we provide horizon scanning intelligence on anti-obesity medicines that are in clinical development so market regulators, reimbursement agencies, industry and health services are informed about medicines currently in the clinical development pipeline. Using horizon scanning techniques a search was performed across clinical trial registries and the National Institute for Health Research (NIHR) Innovation Observatory’s (IO) Medicines Innovation Database (MInD) to identify medicines investigating obesity. Trials were screened for eligibility and data extracted by one reviewer with quality assurance checks conducted by a second reviewer. We identified 47 unique medicines in pre-clinical development and 177 unique medicines in over 405 clinical trials. Just under one quarter of identified medicines had a valid marketing authorisation in the UK. Drug development activity appears to be driven by GLP-1RA therapies, with semaglutide, tirzepatide and liraglutide being studied actively in high volumes of clinical trials with many participants. By sharing this early signalling, we believe key stakeholders will be better prepared to monitor promising anti-obesity medicines in the clinical development pipeline and be in an optimal position to facilitate timely patient access to clinically and cost-effective medicines at pace and at scale.